Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1226)	6/29/1998 10:40:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2742

Rudy: Galton just doesn't understand...... the thing that rings on his desk is used to communicate with the outside world. Brucie... repeat after me..... "Tell....Uh.....Fone". Rick

To: Rudy Saucillo who wrote (1226)	6/29/1998 12:11:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

CIST shareholders: CIST BOD Frank Stout responded to me on the E-mail address Rudy gave us. You may want to express your concerns to him also. The e-mail address again>> frank.stout@es.nemc.org

To: Rudy Saucillo who wrote (1226)	6/29/1998 3:58:00 PM
From: Rudy Saucillo	Respond to of 2742

<<In today's news, SIBI acquires adjuvant technology for cancer and infectious disease applications.>> Uhhhh, that would be RIBI...Freudian slip; I was reading SIBI material last night. Rudy

To: Rudy Saucillo who wrote (1226)	6/30/1998 4:05:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

In today's news, Corixa (another vaccine technology company focused on cancer and infectious disease) presents at Cruttenden Roth. biz.yahoo.com "Corixa offers proprietary advances in three areas of vaccine technology; (1) antigens that trigger an immune response; (2) molecular mechanisms of vaccine delivery, ensuring this response is generated; and (3) adjuvants that encourage and strengthen this response. Corixa follows a "partner early and often" credo, minimizing cash burn, sharing risk and accelerating this development of new vaccines and diagnostics for cancer and infectious diseases." Rudy